Two Leading Stem Cell and Regenerative Medicine Advocacy Groups Announce Merger Plan The Genetics Policy Institute and the Regenerative Medicine Foundation have agreed to merge in order to leverage their resources in the advancement of stem cell research, regenerative medicine and other advanced technologies targeting cures. [Genetics Policy Institute (GlobeNewswire, Inc.)] Press Release FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Amgen announced that the U.S. Food and Drug Administration (FDA) has granted approval of BLINCYTO™ for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [Amgen Inc.] Press Release Prothena Initiates NEOD001 Global Phase III Registrational Trial Based on Positive Results in Ongoing Phase I/II Study of NEOD001 in Patients with AL Amyloidosis Prothena Corporation plc announced the initiation of the VITAL Amyloidosis Study, an international, multi-center, registrational Phase III clinical trial, based on positive results from an ongoing Phase I/II clinical study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. [Prothena Corporation plc] Press Release CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of Seven More Clinical Sites CEL-SCI Corporation announced that it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. [CEL-SCI Corporation] Press Release TxCell Announces Start of Phase IIb Clinical Trial with Ovasave® for Refractory Crohn’s Disease TxCell SA announced that it has enrolled the first patient in its Phase IIb clinical trial of its lead product Ovasave® in refractory Crohn’s disease. [TxCell SA] Press Release Juno Therapeutics Executes License for Phase I CAR T Product Candidate Targeting CD22 for Hematological Malignancies Juno Therapeutics, Inc. announced that it has entered into an agreement to obtain a license from Opus Bio, Inc. for a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. [Juno Therapeutics, Inc.] Press Release Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases Alnylam Pharmaceuticals, Inc. announced that it has filed a CTA with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Phase I/II clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. [Alnylam Pharmaceuticals, Inc.] Press Release Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform Pfizer Inc. announced two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. [Pfizer Inc.] Press Release The Pacific Meso Center Receives $100,000 Donation for Ongoing Stem Cell Research Program Citing the need to invest in a long-range cure, Roger Worthington of the Worthington & Caron, P.C. donated $100,000 to The Pacific Meso Center at The Pacific Heart, Lung & Blood Institute to support its ongoing stem cell research program. [The Pacific Heart, Lung & Blood Institute] Press Release |